αAlphaOS

House committee investigates Merck, AbbVie over China trials

July 2, 2026 · 11 sources · High impact · Updated Jul 21, 2026

Bristol Myers Squibb is expanding its artificial intelligence collaboration with Nvidia, deploying an Nvidia DGX SuperPOD to enhance its drug discovery and development capabilities. This move signifies a deeper integration of AI in pharmaceutical research and strengthens the partnership between the two companies.

Affected Companies

MRK84 ▲5
Merck & Co., Inc.
$123.61$305.29B cap
ABBV61 ▲2
AbbVie Inc.
$253.38$447.67B cap
LLY57 ▼3
ELI LILLY & Co
$1,179.11$1.11T cap
PFE62 ▲2
PFIZER INC
$25.05$142.77B cap
BMY65 ▼2
BRISTOL MYERS SQUIBB CO
$57.58$117.58B cap
SLS63 ▲5
SELLAS Life Sciences Group, Inc.
$12.48$2.32B cap
NVDA98 ▲7
NVIDIA Corporation
$203.28$4.92T cap
QS63 ▲5
QuantumScape Corp
$6.57$627.11M cap
USOJPMBACCRCLSRXHQQQSPYMRVLDIAAAPLGSWFCMSDGX

Affected Industries

Pharmaceuticals60
ExpansionStrong momentumTop 25%
Banks—Diversified40
Early RecoveryStrong momentumTop 72%
AI Infrastructure35
ContractionWeak momentumTop 86%
Capital Markets56
RecoveryStrong momentumTop 34%
Semiconductors46
RecoveryWeak momentumTop 61%
Cloud Software39
ContractionModerate momentumTop 73%

AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.